Oppenheimer Maintains Acadia Pharmaceuticals (ACAD) Perform Recommendation
Fintel reports that on July 14, 2023, Oppenheimer maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform recommendation. Analyst Price Forecast Suggests 2.06% Downside